Literature DB >> 33785612

A peptide of the N terminus of GRK5 attenuates pressure-overload hypertrophy and heart failure.

Ryan C Coleman1, Akito Eguchi1, Melissa Lieu1, Rajika Roy1, Eric W Barr1, Jessica Ibetti1, Anna-Maria Lucchese1, Amanda M Peluzzo1, Kenneth Gresham1, J Kurt Chuprun1, Walter J Koch2.   

Abstract

Aberrant changes in gene expression underlie the pathogenesis and progression of pressure-overload heart failure, leading to maladaptive cardiac hypertrophy, ventricular remodeling, and contractile dysfunction. Signaling through the G protein Gq triggers maladaptation and heart failure, in part through the activation of G protein-coupled receptor kinase 5 (GRK5). Hypertrophic stimuli induce the accumulation of GRK5 in the nuclei of cardiomyocytes, where it regulates pathological gene expression through multiple transcription factors including NFAT. The nuclear targeting of GRK5 is mediated by an amino-terminal (NT) domain that binds to calmodulin (CaM). Here, we sought to prevent GRK5-mediated pathology in pressure-overload maladaptation and heart failure by expressing in cardiomyocytes a peptide encoding the GRK5 NT (GRK5nt) that encompasses the CaM binding domain. In cultured cardiomyocytes, GRK5nt expression abrogated Gq-coupled receptor-mediated hypertrophy, including attenuation of pathological gene expression and the transcriptional activity of NFAT and NF-κB. We confirmed that GRK5nt bound to and blocked Ca2+-CaM from associating with endogenous GRK5, thereby preventing GRK5 nuclear accumulation after pressure overload. We generated mice that expressed GRKnt in a cardiac-specific fashion (TgGRK5nt mice), which exhibited reduced cardiac hypertrophy, ventricular dysfunction, pulmonary congestion, and cardiac fibrosis after chronic transverse aortic constriction. Together, our data support a role for GRK5nt as an inhibitor of pathological GRK5 signaling that prevents heart failure.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33785612      PMCID: PMC8092419          DOI: 10.1126/scisignal.abb5968

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  48 in total

Review 1.  Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease.

Authors:  Petronila Penela; Cristina Murga; Catalina Ribas; Antonio S Tutor; Sandra Peregrín; Federico Mayor
Journal:  Cardiovasc Res       Date:  2005-11-08       Impact factor: 10.787

2.  A rapid technique for the isolation and purification of adult cardiac muscle cells having respiratory control and a tolerance to calcium.

Authors:  T Powell; V W Twist
Journal:  Biochem Biophys Res Commun       Date:  1976-09-07       Impact factor: 3.575

3.  A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.

Authors:  J D Molkentin; J R Lu; C L Antos; B Markham; J Richardson; J Robbins; S R Grant; E N Olson
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

Review 4.  Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling.

Authors:  Arun K Shukla; Kunhong Xiao; Robert J Lefkowitz
Journal:  Trends Biochem Sci       Date:  2011-07-20       Impact factor: 13.807

5.  Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats.

Authors:  Xian Ping Yi; A Martin Gerdes; Faqian Li
Journal:  Hypertension       Date:  2002-06       Impact factor: 10.190

6.  G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.

Authors:  Peng Liu; Xiaoying Wang; Ning Gao; Hua Zhu; Xiaowei Dai; Yanfeng Xu; Chunmei Ma; Lan Huang; Yali Liu; Chuan Qin
Journal:  Brain Res       Date:  2009-10-21       Impact factor: 3.252

Review 7.  Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease.

Authors:  Jonathan A Hata; Walter J Koch
Journal:  Mol Interv       Date:  2003-08

8.  A peptide of the RGS domain of GRK2 binds and inhibits Gα(q) to suppress pathological cardiac hypertrophy and dysfunction.

Authors:  Sarah M Schumacher; Erhe Gao; Maya Cohen; Melissa Lieu; J Kurt Chuprun; Walter J Koch
Journal:  Sci Signal       Date:  2016-03-22       Impact factor: 8.192

9.  Nuclear translocation of cardiac G protein-Coupled Receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process.

Authors:  Jessica I Gold; Jeffrey S Martini; Jonathan Hullmann; Erhe Gao; J Kurt Chuprun; Linda Lee; Douglas G Tilley; Joseph E Rabinowitz; Julie Bossuyt; Donald M Bers; Walter J Koch
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  The Amino-Terminal Domain of GRK5 Inhibits Cardiac Hypertrophy through the Regulation of Calcium-Calmodulin Dependent Transcription Factors.

Authors:  Daniela Sorriento; Gaetano Santulli; Michele Ciccarelli; Angela Serena Maione; Maddalena Illario; Bruno Trimarco; Guido Iaccarino
Journal:  Int J Mol Sci       Date:  2018-03-15       Impact factor: 5.923

View more
  5 in total

Review 1.  Emerging therapeutic targets for cardiac hypertrophy.

Authors:  Alexander J Winkle; Drew M Nassal; Rebecca Shaheen; Evelyn Thomas; Shivangi Mohta; Daniel Gratz; Seth H Weinberg; Thomas J Hund
Journal:  Expert Opin Ther Targets       Date:  2022-01-27       Impact factor: 6.902

2.  Genetic Catalytic Inactivation of GRK5 Impairs Cardiac Function in Mice Via Dysregulated P53 Levels.

Authors:  Federica Marzano; Daniela Liccardo; Andrea Elia; Ines Mucio; Claudio de Lucia; Anna Maria Lucchese; Erhe Gao; Nicola Ferrara; Antonio Rapacciuolo; Nazareno Paolocci; Giuseppe Rengo; Walter J Koch; Alessandro Cannavo
Journal:  JACC Basic Transl Sci       Date:  2022-03-09

Review 3.  Therapeutic targets for cardiac fibrosis: from old school to next-gen.

Authors:  Joshua G Travers; Charles A Tharp; Marcello Rubino; Timothy A McKinsey
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

4.  SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.

Authors:  Li Ma; Rongjun Zou; Wanting Shi; Na Zhou; Shaoxian Chen; Hao Zhou; Xinxin Chen; Yueheng Wu
Journal:  Theranostics       Date:  2022-06-27       Impact factor: 11.600

Review 5.  Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases.

Authors:  Emanuel Guajardo-Correa; Juan Francisco Silva-Agüero; Ximena Calle; Mario Chiong; Mauricio Henríquez; Gerardo García-Rivas; Mauricio Latorre; Valentina Parra
Journal:  Front Cell Dev Biol       Date:  2022-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.